1. US Department of Health and Human Services, Office for Human Research Protections. Code of Federal Regulations Title 45 — Public Welfare. Part 46: Protection of Human Subjects. http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html. Revised January 15, 2009. Accessed April 11, 2012.
2. US Department of Health and Human Services. Code of Federal Regulations Title 21 — Food and Drugs. Chapter I — Food and Drug Administration, subchapter A, part 56: Institutional Review Boards. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?cfrpart=56. Updated April 1, 2011. Accessed April 11, 2012.
3. US Department of Health and Human Services. Code of Federal Regulations Title 21 — Food and Drugs. Chapter 1 — Food and Drug Administration: Part 312 — Investigational New Drug application, section 312.32, IND safety reporting. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.32. Revised April 1, 2011. Accessed August 23, 2012.
4. US Department of Health and Human Services, Office for Human Research Protections. Guidance on reviewing and reporting unanticipated problems involving risks to subjects or others and adverse events. http://www.hhs.gov/ohrp/policy/advevntguid.html. Published January 15, 2007. Accessed April 11, 2012.
5. International Conference on Harmonisation. ICH harmonised tripartite guideline for good clinical practice E6(R1). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf. Published June 10, 1996. Accessed March 30, 2012.